 ZURICH-SCHLIEREN, Switzerland, Sept. 03, 2021 GLOBE NEWSWIRE -- Molecular Partners AG SIX: MOLN, NASDAQ: MOLN, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at two upcoming virtual healthcare investor events in September 2021. 